Annual report pursuant to Section 13 and 15(d)

Segment, Geographical and Other Revenue Information - Concentration Risk (Details)

v3.19.3.a.u2
Segment, Geographical and Other Revenue Information - Concentration Risk (Details)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Merck | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 28.00% 29.00% 28.00%
Merck | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 38.00% 37.00%  
Novartis | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 23.00%   14.00%
Novartis | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage   11.00%  
Nestle Health Science | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage 15.00% 22.00% 15.00%
Nestle Health Science | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 10.00% 17.00%  
Tate & Lyle | Revenue, Product and Service Benchmark      
Concentration Risk [Line Items]      
Concentration risk, percentage   13.00% 11.00%
Kyorin Pharmaceutical Co Ltd | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage   16.00%